Form 4: Eli Lilly EVP Skovronsky Acquires $16.2M in LLY Stock

Eli Lilly's EVP Daniel Skovronsky acquired over 15,500 shares of common stock at a price of $1,044.67 per share, increasing his direct beneficial ownership.

Summary

• Daniel Skovronsky, EVP, CS&PO & Pres. LRL of Eli Lilly & Co (LLY), acquired 15,547.862 shares of common stock.
• The transaction occurred on February 9, 2026, at a price of $1,044.67 per share.
• Following this acquisition, Skovronsky directly owns 160,071.725 shares of Eli Lilly common stock.
• Indirect beneficial ownership includes 72,359 shares held by a Trust, 547 shares by a spouse, and 2,710 shares by a spouse's SLAT.
• The total value of the acquired shares is approximately $16,249,999.99 (15,547.862 * $1,044.67).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating executive confidence in Eli Lilly's future performance and stock value, which can reassure investors.

Positives

• An executive's acquisition of company stock can signal confidence in the company's future prospects and valuation.
• The significant value of the acquisition, approximately $16.2 million, demonstrates a substantial personal investment by a key executive.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Eli Lilly's future outlook.

Management Comments

• The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider buying, especially by high-level executives, is often viewed positively by the market as it suggests management believes the company's stock is undervalued or has strong future growth potential. In the pharmaceutical industry, executive confidence can be particularly impactful given the long development cycles and regulatory hurdles.

Comparison to Industry Standards

• StockSavvy.ai observes that executive stock purchases are a common practice across industries. While the specific amount of shares acquired by Daniel Skovronsky is substantial, it is difficult to benchmark against specific comparable companies or projects without more context on his total compensation and existing holdings relative to peers at companies like Pfizer, Johnson & Johnson, or Merck. However, an acquisition of this magnitude by an EVP is generally considered a strong signal of confidence.

Related Party Transactions

• Indirect beneficial ownership through a Trust, spouse, and spouse's SLAT are disclosed, which are common related party arrangements for executive stock holdings.

Stakeholder Impact

• Shareholders may view this executive stock purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• Employees may see this as a sign of stability and positive future prospects for the company.

Key Dates

Recommendation

The significant acquisition of company stock by a high-ranking executive like Daniel Skovronsky, valued at over $16 million, signals strong insider confidence in Eli Lilly's future prospects and current valuation. Such a substantial personal investment often precedes positive company performance, making it a compelling 'buy' signal for seasoned investors.

Keywords

Eli Lilly, LLY, Daniel Skovronsky, Insider Trading, Stock Acquisition, Form 4, Executive Ownership, Pharmaceuticals, Biotechnology